Tumor Biology

, Volume 36, Issue 2, pp 633–641 | Cite as

GRP78 mediates the therapeutic efficacy of curcumin on colon cancer

  • Yu-Jia Chang
  • Chien-Yu Huang
  • Chin-Sheng Hung
  • Wei-Yu Chen
  • Po-Li Wei
Research Article


Glucose-regulated protein 78 (GRP78) is the key regulator of endoplasmic reticular (ER) function. Expression of GRP78 was correlated with malignancy in different cancers. However, the role of GRP78 in the cytotoxic effect of curcumin on colon cancer cells is still unclear. A silencing RNA (siRNA) technique was used to knock down GRP78 expression. The anticancer effects of curcumin were assessed by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, a flow cytometric cell cycle analysis, and a terminal dexynucleotidyl transferase-mediated nick end labeling (TUNEL) assay. HT-29 cells expressed lower GRP78 compared with DLD-1 cells. The MTT assay revealed that HT-29 cells were more resistant to curcumin treatment than DLD-1 cells. GRP78KD cells showed more resistance to curcumin treatment compared with scrambled control cells. Overexpressed GRP78 in HT-29 cells increased the sensitivity to curcumin treatment. According to the cell cycle analysis and TUNEL assay, we found that apoptosis dramatically increased in scrambled control cells compared to GRP78KD DLD-1 cells after curcumin treatment. Finally, we evaluated levels of Bcl-2, BAX, and Bad and found that an increase of Bcl-2 level was observed in GRP78KD cells treated with curcumin. Those results were consistent with the increasing of resistance to curcumin after silencing of GRP78. The levels of GRP78 expression might determine the therapeutic efficacy of curcumin against colon cancer cells.


Colon cancer Antiproliferation Curcumin GRP78 



Glucose-regulated protein 78


Endoplasmic reticulum



This study was supported by grants from National Science Council (NSC101-2314-B-038-029-MY3 and NSC101-2314-B-038-016-MY3).

Conflicts of interest



  1. 1.
    Basnet P, Skalko-Basnet N. Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules. 2011;16:4567–98.CrossRefPubMedGoogle Scholar
  2. 2.
    Gupta SC, Patchva S, Koh W, Aggarwal BB. Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clinic Experiment Pharmacol Physiol. 2012;39:283–99.CrossRefGoogle Scholar
  3. 3.
    Anand P, Thomas SG, Kunnumakkara AB, Sundaram C, Harikumar KB, Sung B, et al. Biological activities of curcumin and its analogues (congeners) made by man and mother nature. Biochem Pharmacol. 2008;76:1590–611.CrossRefPubMedGoogle Scholar
  4. 4.
    Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett. 2008;269:199–225.CrossRefPubMedGoogle Scholar
  5. 5.
    Shehzad A, Lee YS. Molecular mechanisms of curcumin action: signal transduction. Biofactors. 2013;39:27–36.CrossRefPubMedGoogle Scholar
  6. 6.
    Zhou H, Beevers CS, Huang S. The targets of curcumin. Curr Drug Targets. 2011;12:332–47.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Park W, Amin AR, Chen ZG, Shin DM. New perspectives of curcumin in cancer prevention. Cancer Prev Res (Phila). 2013;6:387–400.CrossRefGoogle Scholar
  8. 8.
    Hasima N, Aggarwal BB. Cancer-linked targets modulated by curcumin. Int J Biochem Molec Biol. 2012;3:328–51.Google Scholar
  9. 9.
    Ravindran J, Prasad S, Aggarwal BB. Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J. 2009;11:495–510.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Fu S, Kurzrock R. Development of curcumin as an epigenetic agent. Cancer. 2010;116:4670–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Goel A, Aggarwal BB. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer. 2010;62:919–30.CrossRefPubMedGoogle Scholar
  12. 12.
    Li J, Lee AS. Stress induction of grp78/bip and its role in cancer. Curr Mol Med. 2006;6:45–54.CrossRefPubMedGoogle Scholar
  13. 13.
    Lee E, Nichols P, Spicer D, Groshen S, Yu MC, Lee AS. Grp78 as a novel predictor of responsiveness to chemotherapy in breast cancer. Cancer Res. 2006;66:7849–53.CrossRefPubMedGoogle Scholar
  14. 14.
    Zhu X, Lin MC, Fan W, Tian L, Wang J, Ng SS, et al. An intronic polymorphism in grp78 improves chemotherapeutic prediction in non-small cell lung cancer. Chest. 2012;141:1466–72.CrossRefPubMedGoogle Scholar
  15. 15.
    Pootrakul L, Datar RH, Shi SR, Cai J, Hawes D, Groshen SG, et al. Expression of stress response protein grp78 is associated with the development of castration-resistant prostate cancer. Clin Cancer Res. 2006;12:5987–93.CrossRefPubMedGoogle Scholar
  16. 16.
    Delie F, Petignat P, Cohen M. Grp78 protein expression in ovarian cancer patients and perspectives for a drug-targeting approach. J Oncol. 2012;2012:468615.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Wang HQ, Du ZX, Zhang HY, Gao DX. Different induction of grp78 and chop as a predictor of sensitivity to proteasome inhibitors in thyroid cancer cells. Endocrinology. 2007;148:3258–70.CrossRefPubMedGoogle Scholar
  18. 18.
    Li Z, Zhang L, Zhao Y, Li H, Xiao H, Fu R, et al. Cell-surface grp78 facilitates colorectal cancer cell migration and invasion. Int J Biochem Cell Biol. 2013;45:987–94.CrossRefPubMedGoogle Scholar
  19. 19.
    Reddy RK, Mao C, Baumeister P, Austin RC, Kaufman RJ, Lee AS. Endoplasmic reticulum chaperone protein grp78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation. J Biol Chem. 2003;278:20915–24.CrossRefPubMedGoogle Scholar
  20. 20.
    Ranganathan AC, Zhang L, Adam AP, Aguirre-Ghiso JA. Functional coupling of p38-induced up-regulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells. Cancer Res. 2006;66:1702–11.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 2009;18:1688–94.CrossRefPubMedGoogle Scholar
  22. 22.
    Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009;59:366–78.CrossRefPubMedGoogle Scholar
  23. 23.
    Benson 3rd AB, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22:3408–19.CrossRefPubMedGoogle Scholar
  24. 24.
    Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–45.CrossRefPubMedGoogle Scholar
  25. 25.
    El Zouhairi M, Charabaty A, Pishvaian MJ. Molecularly targeted therapy for metastatic colon cancer: proven treatments and promising new agents. Gastrointest Cancer Res. 2011;4:15–21.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.CrossRefPubMedGoogle Scholar
  27. 27.
    Wu CT, Wang WC, Chen MF, Su HY, Chen WY, Wu CH, et al. Glucose-regulated protein 78 mediates hormone-independent prostate cancer progression and metastasis through maspin and cox-2 expression. Tumour Biol J Int Soc Oncodeve Biol Med. 2014;35:195–204.CrossRefGoogle Scholar
  28. 28.
    Tai CJ, Wang JW, Su HY, Wang CK, Wu CT, Lien YC, et al. Glucose-regulated protein 94 modulates the therapeutic efficacy to taxane in cervical cancer cells. Tumour Biol J Int Soc Oncodeve Biol Med. 2014;35:403–10.CrossRefGoogle Scholar
  29. 29.
    Chiou JF, Tai CJ, Huang MT, Wei PL, Wang YH, An J, et al. Glucose-regulated protein 78 is a novel contributor to acquisition of resistance to sorafenib in hepatocellular carcinoma. Ann Surg Oncol. 2010;17:603–12.CrossRefPubMedGoogle Scholar
  30. 30.
    Chang YJ, Chiu CC, Wu CH, An J, Wu CC, Liu TZ, et al. Glucose-regulated protein 78 (grp78) silencing enhances cell migration but does not influence cell proliferation in hepatocellular carcinoma. Ann Surg Oncol. 2010;17:1703–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Chen B, Zhang Y, Wang Y, Rao J, Jiang X, Xu Z: Curcumin inhibits proliferation of breast cancer cells through nrf2-mediated down-regulation of fen1 expression. The Journal of Steroid Biochemistry and Molecular Biology 2014.Google Scholar
  32. 32.
    Xie YQ, Wu XB, Tang SQ. Curcumin treatment alters erk-1/2 signaling in vitro and inhibits nasopharyngeal carcinoma proliferation in mouse xenografts. Int J Clinic Experiment Med. 2014;7:108–14.Google Scholar
  33. 33.
    Bansal SS, Goel M, Aqil F, Vadhanam MV, Gupta RC. Advanced drug delivery systems of curcumin for cancer chemoprevention. Cancer Prev Res (Phila). 2011;4:1158–71.CrossRefGoogle Scholar
  34. 34.
    Agrawal DK, Mishra PK. Curcumin and its analogues: potential anticancer agents. Med Res Rev. 2010;30:818–60.PubMedGoogle Scholar
  35. 35.
    Shehzad A, Wahid F, Lee YS. Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch Pharm. 2010;343:489–99.CrossRefGoogle Scholar
  36. 36.
    Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clinic Cancer Res Off J Am Assoc Cancer Res. 2008;14:4491–9.CrossRefGoogle Scholar
  37. 37.
    Patel VB, Misra S, Patel BB, Majumdar AP. Colorectal cancer: chemopreventive role of curcumin and resveratrol. Nutr Cancer. 2010;62:958–67.CrossRefPubMedGoogle Scholar
  38. 38.
    Epelbaum R, Schaffer M, Vizel B, Badmaev V, Bar-Sela G. Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr Cancer. 2010;62:1137–41.CrossRefPubMedGoogle Scholar
  39. 39.
    Kanai M, Yoshimura K, Asada M, Imaizumi A, Suzuki C, Matsumoto S, et al. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol. 2011;68:157–64.CrossRefPubMedGoogle Scholar
  40. 40.
    Grynkiewicz G, Slifirski P. Curcumin and curcuminoids in quest for medicinal status. Acta Biochim Pol. 2012;59:201–12.PubMedGoogle Scholar
  41. 41.
    Shehzad A, Lee J, Huh TL, Lee YS: Curcumin induces apoptosis in human colorectal carcinoma (hct-15) cells by regulating expression of prp4 and p53. Molecules and cells 2013.Google Scholar
  42. 42.
    Kim HJ, Park SY, Park OJ, Kim YM. Curcumin suppresses migration and proliferation of Hep3B hepatocarcinoma cells through inhibition of the Wnt signaling pathway. Molec Med Rep. 2013;8:282–6.Google Scholar
  43. 43.
    Teiten MH, Dicato M, Diederich M: Curcumin as a regulator of epigenetic events. Molecular nutrition & food research 2013.Google Scholar
  44. 44.
    Pichu S, Krishnamoorthy S, Shishkov A, Zhang B, McCue P, Ponnappa BC. Knockdown of ki-67 by dicer-substrate small interfering rna sensitizes bladder cancer cells to curcumin-induced tumor inhibition. PLoS One. 2012;7:e48567.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Chang YJ, Tai CJ, Kuo LJ, Wei PL, Liang HH, Liu TZ, et al. Glucose-regulated protein 78 (grp78) mediated the efficacy to curcumin treatment on hepatocellular carcinoma. Ann Surg Oncol. 2011;18:2395–403.CrossRefPubMedGoogle Scholar
  46. 46.
    Sato M, Yao VJ, Arap W, Pasqualini R. Grp78 signaling hub a receptor for targeted tumor therapy. Adv Genet. 2010;69:97–114.PubMedGoogle Scholar
  47. 47.
    Brostrom MA, Brostrom CO. Calcium dynamics and endoplasmic reticular function in the regulation of protein synthesis: implications for cell growth and adaptability. Cell Calcium. 2003;34:345–63.CrossRefPubMedGoogle Scholar
  48. 48.
    Wang JY, Chen BK, Wang YS, Tsai YT, Chen WC, Chang WC, et al. Involvement of store-operated calcium signaling in egf-mediated cox-2 gene activation in cancer cells. Cell Signal. 2012;24:162–9.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Yu-Jia Chang
    • 1
    • 2
    • 3
    • 4
  • Chien-Yu Huang
    • 5
    • 6
  • Chin-Sheng Hung
    • 2
    • 3
    • 4
  • Wei-Yu Chen
    • 7
    • 8
  • Po-Li Wei
    • 2
    • 3
    • 4
  1. 1.Graduate Institute of Clinical MedicineCollege of Medicine, Taipei Medical UniversityTaipeiTaiwan
  2. 2.Department of SurgerySchool of Medicine, College of Medicine, Taipei Medical UniversityTaipeiTaiwan
  3. 3.Division of General Surgery, Department of Surgery, Taipei Medical University HospitalTaipei Medical UniversityTaipeiTaiwan
  4. 4.Cancer Research CenterTaipei Medical University Hospital, Taipei Medical UniversityTaipeiTaiwan
  5. 5.Division of General Surgery, Department of SurgeryShuang Ho Hospital, Taipei Medical UniversityTaipeiTaiwan
  6. 6.Department of NeurosurgeryShuang Ho Hospital, Taipei Medical UniversityTaipeiTaiwan
  7. 7.Department of PathologySchool of Medicine, College of Medicine, Taipei Medical UniversityTaipeiTaiwan
  8. 8.Department of PathologyWan Fang Hospital, Taipei Medical UniversityTaipeiTaiwan

Personalised recommendations